Review · United States
Teduglutide
Reviewed on
Approval and product status
Teduglutide is a 33-amino-acid GLP-2 analog. In the United States, Gattex (teduglutide) is FDA-approved for people age 1 and older who have short bowel syndrome and depend on fluids or nutrition given through a vein.
Gattex evidence applies to a specific monitored prescription product. Gattex is a labeled prescription product used with structured monitoring. Its evidence does not establish general gut healing or equivalence for compounded GLP-2 analogues.
What was measured in people?
- Health results · Strong
- Randomized trials support reduction in parenteral-support requirements for short bowel syndrome.
- Body changes · Strong
- Intestinal absorption, exposure, and product effects are characterized in the label and trials.
A change in a hormone or body signal does not by itself prove a health benefit.
Important limits
This tool is not an independent medical review. It does not recommend treatment.
This monitored prescription therapy has serious risks, including possible acceleration of neoplastic growth. No dosing, reconstitution, or self-treatment guidance is provided.
Still unknown: The evidence does not establish broad treatment of leaky gut, inflammatory symptoms, wellness, or mucosal repair in people without the labeled syndrome.
This record cannot check a package, seller, batch, or personal treatment. It does not provide sport clearance.
Products in this review
These are selected records, not every product or form.
Gattex
- Ingredients and form
- Powder and diluent for injection
- How it enters the body
- Under the skin (subcutaneous)
- Use and people covered
- Short bowel syndrome with parenteral-support dependence in the adult and pediatric populations defined in the label.
Published label: 2025 label
Read the published Gattex FDA label (PDF)What the research shows
Randomized trials found that some participants needed less fluid or nutrition through a vein. The product label defines required screening and ongoing monitoring.
Read all Teduglutide fact checksSources used in this review
A source may support some statements, not all of them. Use the links above or this review to see what each source supports.
Show 3 sources
- GATTEX (teduglutide) prescribing information
U.S. Food and Drug Administration · Drug label · 2025
Source accessed
- Teduglutide reduces parenteral support in short bowel syndrome
PubMed · Gastroenterology · Randomized trial · 2012
Source accessed
- Teduglutide orphan drug designation and approval
U.S. Food and Drug Administration · Regulatory · 2019
Source accessed